John T Isaacs

List of Publications by Year in Descending Order

158 papers	13,515 citations	60 h-index	114 g-index
169 ext. papers	14,768 ext. citations	7 avg, IF	6.36 L-index

#	Paper	IF	Citations
158	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. *Cancer Research*, **2021**, 81, 5948-5962	10.1	3
157	Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. *JCI Insight*, **2021**, 6,	9.9	5
156	Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. *Immunotherapy*, **2021**, 13, 155-175	3.8	6
155	From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development. *Progress in the Chemistry of Organic Natural Products*, **2021**, 115, 59-114	1.9	0
154	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. *European Journal of Cancer*, **2021**, 144, 302-309	7.5	3
153	Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. *Cell Reports*, **2020**, 31, 107669	10.6	55
152	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. *Oncogene*, **2020**, 39, 6935-6949	9.2	19
151	Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer. *Molecular Cancer Therapeutics*, **2020**, 19, 2353-2362	6.1	1
150	Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. *Asian Journal of Urology*, **2019**, 6, 99-108	2.7	10
149	Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. *Prostate*, **2019**, 79, 1326-1337	4.2	10
148	Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. *Cancer Research*, **2019**, 79, 3636-3650	10.1	27
147	In Reply. *Stem Cells Translational Medicine*, **2019**, 8, 739-740	6.9	1
146	A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. *Stem Cells Translational Medicine*, **2019**, 8, 441-449	6.9	33
145	Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 386-389	10.2	7
144	Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?. *Prostate*, **2019**, 79, 320-330	4.2	36
143	2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer. *Prostate*, **2018**, 78, 655-663	4.2	4
142	The what, when, and why of human prostate cancer xenografts. *Prostate*, **2018**, 78, 646-654	4.2	9

141	Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. *Stem Cells Translational Medicine*, **2018**, 7, 651-663	6.9	119
140	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. *Prostate*, **2018**, 78, 1262-1282	4.2	44
139	Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?. *American Journal of Clinical and Experimental Urology*, **2018**, 6, 55-61	1.6	3
138	Mesenchymal stem cells and the embryonic reawakening theory of BPH. *Nature Reviews Urology*, **2018**, 15, 703-715	5.5	19
137	Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy. *Cancer Cell*, **2017**, 32, 399-401	24.3	13
136	Low p16 Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone. *Prostate*, **2017**, 77, 374-384	4.2	6
135	Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. *Oncotarget*, **2017**, 8, 46710-46727	3.3	20
134	A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. *Biomaterials*, **2016**, 91, 140-150	15.6	55
133	Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation. *Clinical Cancer Research*, **2016**, 22, 3310-3319	12.9	25
132	Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. *Oncotarget*, **2016**, 7, 71298-71308	3.3	11
131	Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. *Prostate*, **2016**, 76, 552-64	4.2	17
130	Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 4651-63	12.9	29
129	Lessons learned about prostatic transformation from the age-related methylation of 5□reductase type 2 gene. *American Journal of Pathology*, **2015**, 185, 614-6	5.8	2
128	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. *Science Translational Medicine*, **2015**, 7, 269ra2	17.5	149
127	Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. *Cancer Research*, **2014**, 74, 3390-5	10.1	2
126	4-Hy-droxy-5-meth-oxy-N,1-dimethyl-2-oxo-N-[4-(tri-fluoro-meth-yl)phen-yl]-1,2-di-hydro-quinoline-3-carboxamide. *Acta Crystallographica Section E: Structure Reports Online*, **2014**, 70, o297-8		
125	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *New England Journal of Medicine*, **2014**, 371, 1028-38	59.2	1753
124	Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. *International Journal of Biological Sciences*, **2014**, 10, 627-42	11.2	61

123	Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate. *Prostate*, **2014**, 74, 805-10	4.2	2
122	Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/□catenin/TCF-4 complex inhibition of c-MYC transcription. *Prostate*, **2014**, 74, 1118-31	4.2	44
121	Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. *Prostate*, **2014**, 74, 1308-19	4.2	18
120	Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. *Oncotarget*, **2014**, 5, 8093-106	3.3	8
119	Cancer. Prostate cancer takes nerve. *Science*, **2013**, 341, 134-5	33.3	12
118	Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. *Cancer Research*, **2013**, 73, 1386-99	10.1	72
117	Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. *Endocrine-Related Cancer*, **2013**, 20, R269-90	5.7	48
116	Of mice and men--warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. *Prostate*, **2013**, 73, 1316-25	4.2	43
115	Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. *Oncotarget*, **2013**, 4, 106-17	3.3	62
114	Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. *Journal of the National Cancer Institute*, **2012**, 104, 1320-34	9.7	130
113	Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. *Prostate*, **2012**, 72, 638-48	4.2	29
112	Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. *Prostate*, **2012**, 72, 1478-89	4.2	16
111	Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. *Prostate*, **2012**, 72, 1491-505	4.2	69
110	Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. *Science Translational Medicine*, **2012**, 4, 140ra86	17.5	159
109	Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. *Molecular Cancer Therapeutics*, **2012**, 11, 257-66	6.1	165
108	Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. *Prostate*, **2011**, 71, 1595-607	4.2	35
107	ANDROGEN RECEPTOR CONVERTS FROM A GROWTH SUPPRESSOR IN THE NORMAL PROSTATE TO AN ONCOGENE IN PROSTATE CANCER **2011**, 53-65		
106	Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. *Molecular Cancer*, **2010**, 9, 107	42.1	69

105	The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. *Expert Opinion on Investigational Drugs*, **2010**, 19, 1235-43	5.9	33
104	Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. *Prostate*, **2010**, 70, 90-9	4.2	37
103	Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. *Prostate*, **2010**, 70, 1600-7	4.2	67
102	Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. *PLoS ONE*, **2010**, 5, e11475	3.7	31
101	Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. *Molecular Cancer Therapeutics*, **2009**, 8, 1340-9	6.1	31
100	DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. *Endocrine-Related Cancer*, **2009**, 16, 325-32	5.7	35
99	Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts. *Prostate*, **2009**, 69, 1557-64	4.2	13
98	Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. *Prostate*, **2009**, 69, 1724-9	4.2	71
97	Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. *Biochemistry*, **2009**, 48, 3490-6	3.2	39
96	A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. *Anti-Cancer Agents in Medicinal Chemistry*, **2009**, 9, 276-94	2.2	74
95	The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. *Cancer Research*, **2008**, 68, 9703-11	10.1	193
94	Prostate stem cells and benign prostatic hyperplasia. *Prostate*, **2008**, 68, 1025-34	4.2	72
93	Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. *Prostate*, **2008**, 68, 1570-81	4.2	9
92	Modulating paclitaxel bioavailability for targeting prostate cancer. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 4973-84	3.4	38
91	Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?. *Prostate*, **2007**, 67, 312-29	4.2	78
90	Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. *Prostate*, **2007**, 67, 799-807	4.2	27
89	The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. *Prostate*, **2007**, 67, 790-7	4.2	52
88	Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. *Cell Cycle*, **2007**, 6, 647-51	4.7	56

87	A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. *Journal of the National Cancer Institute*, **2007**, 99, 376-85	9.7	75
86	Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. *Cancer Research*, **2006**, 66, 8598-607	10.1	118
85	Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. *Clinical Cancer Research*, **2006**, 12, 4072-9	12.9	87
84	Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 15085-90	11.5	95
83	Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. *Prostate*, **2006**, 66, 358-68	4.2	43
82	PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. *Prostate*, **2006**, 66, 1329-38	4.2	76
81	Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. *Prostate*, **2006**, 66, 1768-78	4.2	70
80	Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 2810-5	3.4	65
79	Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. *Cancer Research*, **2005**, 65, 9269-79	10.1	60
78	Androgens and prostate cancer: are the descriptors valid?. *Cancer Biology and Therapy*, **2005**, 4, 4-5	4.6	39
77	Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways. *International Journal of Biochemistry and Cell Biology*, **2005**, 37, 707-14	5.6	32
76	New strategies for the medical treatment of prostate cancer. *BJU International*, **2005**, 96 Suppl 2, 35-40	5.6	38
75	The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. *Cancer Biology and Therapy*, **2005**, 4, 14-22	4.6	178
74	Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. *Cancer Research*, **2004**, 64, 6190-9	10.1	108
73	Hedgehog signalling in prostate regeneration, neoplasia and metastasis. *Nature*, **2004**, 431, 707-12	50.4	895
72	Molecular characterization of the commonly used human androgen receptor expression vector, pSG5-AR. *Prostate*, **2004**, 58, 319-24	4.2	20
71	Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. *Prostate*, **2004**, 61, 299-304	4.2	22
70	In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. *Journal of Cellular Biochemistry*, **2004**, 91, 196-205	4.7	93

69	Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. *Prostate*, **2003**, 54, 249-57	4.2	111
68	Is the AchillesQheel for prostate cancer therapy a gain of function in androgen receptor signaling?. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 2972-82	5.6	179
67	Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. *Journal of the National Cancer Institute*, **2003**, 95, 990-1000	9.7	234
66	CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. *Cancer Research*, **2003**, 63, 5978-91	10.1	77
65	A history of prostate cancer treatment. *Nature Reviews Cancer*, **2002**, 2, 389-96	31.3	414
64	Modified synthesis and antiangiogenic activity of linomide. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 451-2	2.9	14
63	Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. *Prostate*, **2001**, 48, 1-6	4.2	92
62	Mixed lineage kinase (MLK) family members are not involved in androgen regulation of prostatic proliferation or apoptosis. *Prostate*, **2001**, 48, 67-70	4.2	1
61	Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. *Prostate*, **2001**, 48, 71-8	4.2	26
60	Defining a common region of deletion at 13q21 in human cancers. *Genes Chromosomes and Cancer*, **2001**, 31, 333-44	5	29
59	Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. *Journal of Medicinal Chemistry*, **2001**, 44, 4696-703	8.3	110
58	Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. *Prostate*, **2000**, 43, 303-17	4.2	89
57	Rational basis for Trk inhibition therapy for prostate cancer. *Prostate*, **2000**, 45, 140-8	4.2	96
56	Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 1273-80	3.4	59
55	Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome 7. *Genes Chromosomes and Cancer*, **1999**, 24, 1-8	5	19
54	Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. *Prostate*, **1999**, 38, 46-54	4.2	31
53	Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts. *Prostate*, **1999**, 39, 67-70	4.2	4
52	Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. *Prostate*, **1999**, 39, 269-79	4.2	19

51	The biology of hormone refractory prostate cancer. Why does it develop?. *Urologic Clinics of North America*, **1999**, 26, 263-73	2.9	196
50	Identification of the rat homologue of KAI1 and its expression in Dunning rat prostate cancers. *Prostate*, **1998**, 37, 253-60	4.2	9
49	Anti-Angiogenic Treatment with Linomide as Adjuvant to Surgical Castration in Experimental Prostate Cancer. *Journal of Urology*, **1997**, 158, 902-907	2.5	25
48	Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. *Prostate*, **1997**, 32, 205-13	4.2	48
47	Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. *Prostate*, **1997**, 33, 201-7	4.2	46
46	Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. *Journal of Urology*, **1997**, 158, 902-7	2.5	6
45	Metastasis suppressor genes for prostate cancer. *Prostate*, **1996**, 29, 31-35	4.2	19
44	Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. *Prostate*, **1996**, 28, 251-65	4.2	294
43	Development of a high-efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme beta-galactosidase. *Prostate*, **1996**, 29, 60-4	4.2	4
42	The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis. *Prostate*, **1996**, 29, 183-90	4.2	11
41	Expression of homeobox gene-GBX2 in human prostatic cancer cells. *Prostate*, **1996**, 29, 395-8	4.2	15
40	Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer **1996**, 28, 251		9
39	Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. *Prostate*, **1995**, 26, 235-46	4.2	31
38	Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10. *Genes Chromosomes and Cancer*, **1995**, 14, 112-9	5	48
37	Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. *Prostate*, **1994**, 25, 249-65	4.2	70
36	Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation. *Prostate*, **1994**, 25, 301-9	4.2	27
35	Role of androgens in prostatic cancer. *Vitamins and Hormones*, **1994**, 49, 433-502	2.5	102
34	Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. *Nature*, **1993**, 361, 739-42	50.4	459

33	Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. *Prostate*, **1992**, 20, 233-41	4.2	21
32	Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. *Prostate*, **1992**, 21, 15-34	4.2	64
31	Hormonal balance and the risk of prostatic cancer. *Journal of Cellular Biochemistry*, **1992**, 16H, 107-8	4.7	6
30	Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. *International Journal of Cancer*, **1992**, 51, 318-24	7.5	87
29	H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection. *Prostate*, **1991**, 18, 163-72	4.2	28
28	Estramustine binding protein (EMBP) in rat R3327 Dunning tumors: partial characterization and effect of hormonal withdrawal, hormonal replacement, and cytotoxic treatment on its expression. *Prostate*, **1991**, 18, 181-200	4.2	11
27	Role of calcium in the programmed death of rat prostatic glandular cells. *Prostate*, **1990**, 17, 175-87	4.2	99
26	Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma-associated antigens. *Prostate*, **1990**, 17, 317-25	4.2	16
25	Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. *Prostate*, **1990**, 17, 327-36	4.2	15
24	Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. *Prostate*, **1990**, 3, 1-7	4.2	90
23	Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. *Endocrinology*, **1990**, 127, 2963-8	4.8	191
22	Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. *Molecular Endocrinology*, **1989**, 3, 1515-22		367
21	Prostatic growth effects of rat urogenital sinus and human prostatic tissue in the rat. *Prostate*, **1989**, 14, 301-8	4.2	0
20	Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system. *Prostate*, **1989**, 14, 323-39	4.2	24
19	Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. *Prostate*, **1989**, 15, 233-50	4.2	222
18	Etiology and disease process of benign prostatic hyperplasia. *Prostate*, **1989**, 2, 33-50	4.2	378
17	Activation of programmed cell death in the rat ventral prostate after castration. *Endocrinology*, **1988**, 122, 552-62	4.8	581
16	Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. *Endocrinology*, **1988**, 123, 2124-31	4.8	154

15	Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. *Journal of Urology*, **1988**, 140, 1580-6	2.5	46
14	Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer. *Journal of Urology*, **1987**, 138, 427-9	2.5	43
13	Isolation of a 41 kilodalton cytosol protein from the Dunning rat prostatic adenocarcinoma: characterization as depolymerized actin isomers. *Prostate*, **1987**, 10, 303-12	4.2	1
12	Biological significance of measurable androgen levels in the rat ventral prostate following castration. *Prostate*, **1987**, 10, 313-24	4.2	53
11	Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. *Prostate*, **1987**, 11, 41-50	4.2	74
10	Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. *Prostate*, **1986**, 9, 261-81	4.2	350
9	A chicken chorioallantoic membrane assay for the evaluation of the androgen responsiveness of prostatic tissue. *Journal of Urology*, **1986**, 135, 1312-8	2.5	2
8	Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat. *Endocrinology*, **1984**, 114, 511-20	4.8	55
7	The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. *Prostate*, **1984**, 5, 1-17	4.2	164
6	Antagonistic effect of androgen on prostatic cell death. *Prostate*, **1984**, 5, 545-57	4.2	286
5	The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. *Journal of Urology*, **1984**, 131, 694-700	2.5	44
4	Prostatic structure and function in relation to the etiology of prostatic cancer. *Prostate*, **1983**, 4, 351-66	4.2	65
3	Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. *Journal of Clinical Endocrinology and Metabolism*, **1983**, 56, 139-46	5.6	85
2	Testosterone and the prostate268-291		1
1	Supraphysiological testosterone induces ferroptosis and activates NF-kappaB mediated immune pathways in prostate cancer through nucleophagy		1